Observational studyRheumatology international2017

Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors.

Johan Dalén et al.PubMed ↗Publisher ↗

No numbers read from the abstract.